Back to top
more

Montes Archimedes Acquisition (ROIV)

(Delayed Data from NSDQ)

$16.04 USD

16.04
4,849,721

-0.08 (-0.50%)

Updated Oct 10, 2025 04:00 PM ET

After-Market: $16.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 14.29% and 72.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 4.62% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stock Market News for Nov 14, 2023

by Zacks Equity Research

Wall Street closed mixed on Monday as market participants awaited the release of a key inflation data.

Zacks Equity Research

Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data

by Zacks Equity Research

Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 5.66% and 53.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 2.04% and 8.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -6.06% and 2.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche

by Zacks Equity Research

Roivant's (ROIV) RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody, is being developed for ulcerative colitis and Crohn's disease

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Company News for Jun 29, 2023

by Zacks Equity Research

Companies in The News Are: AVAV, UNF, GIS, ROIV.

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of 51.22% and 44.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -52.27% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -36.11% and 19.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

by Zacks Equity Research

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

by Kinjel Shah

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?